Skip to main content
Top
Published in: BMC Pulmonary Medicine 1/2016

Open Access 01-12-2016 | Study protocol

External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)

Authors: Maite Espantoso-Romero, Miguel Román Rodríguez, Ana Duarte-Pérez, Jaime Gonzálvez-Rey, Pedro A. Callejas-Cabanillas, Durdica Kasuba Lazic, Berta Anta-Agudo, Pere Torán Monserrat, Rosa Magallon-Botaya, Biljana Gerasimovska Kitanovska, Heidrun Lingner, Radost S. Assenova, Claudia Iftode, Francisco Gude-Sampedro, Ana Clavería, On behalf of the PROEPOC/COPD study group

Published in: BMC Pulmonary Medicine | Issue 1/2016

Login to get access

Abstract

Background

Due to the heterogeneous and systemic nature of the chronic obstructive pulmonary disease (COPD), the new guidelines are oriented toward individualized attention. Multidimensional scales could facilitate its proper clinical and prognostic assessment, but not all of them were validated in an international primary care cohort, different from the original ones used for model development. Therefore, our main aim is to assess the prognostic capacity of the ADO, BODEx and DOSE indices in primary care for predicting mortality in COPD patients and to validate the models obtained in subgroups of patients, classified by revised Global Initiative for Chronic Obstructive Lung Disease (2011) and updated Spanish Guideline (2014). Besides, we want to confirm that the prognostic capacity of all indices increases if the number of exacerbations is substituted by the interval between them and to assess the impact on health of the patient’s lifestyle, social network and adherence to treatment.

Methods

Design: External validation of scales, open and prospective cohort study in primary care.
Setting: 36 health centres in 6 European high, medium and low income countries.
Subjects: 477 patients diagnosed with COPD, captured in clinical visit by their General Practitioner/Nurse.
Predictors: Detailed patient history, exacerbations, lung function test and questionnaires at baseline.
Outcomes: Exacerbations, all-cause mortality and specific mortality, within 5 years of recruitment.
Analysis: Multivariate logistic regression and Cox regression will be used. Possible non-linear effect of the indices will be studied by using Structured Additive Regression models with penalised splines. Subsequently, we will assess different aspects of the regression models: discrimination, calibration and diagnostic precision. Clinical variables modulated in primary care and the interval between exacerbations will be considered and incorporated into the analysis.

Discussion

The Research Agenda for General Practice/Family Medicine highlights that the evidence on predictive values of prognostic indices in primary care is scarce. A prospective cohort like that of PROEPOC/COPD provides good opportunities for research into COPD and make communication easier between family practitioners, nursing staff, pneumologists and other professionals, supporting a multi-disciplinary approach to the treatment of these patients.

Trial registration

ISRCTN52402811. Date: 15/01/2015. Prospectively registered.
Appendix
Available only for authorised users
Literature
1.
go back to reference Grupo de trabajo de la guía de práctica clínica sobre Atención Integral al paciente con Enfermedad Pulmonar Obstructiva Crónica (EPOC). Desde la Atención Primaria a la Especializada. Sociedad Española de Medicina de Familia (semFYC) y Sociedad Española de Neumología y Cirugía Torácica (SEPAR); 2010. http://www.guiasalud.es/GPC/GPC_468_EPOC_AP_AE.pdf. Accessed 30 Aug 2016. Grupo de trabajo de la guía de práctica clínica sobre Atención Integral al paciente con Enfermedad Pulmonar Obstructiva Crónica (EPOC). Desde la Atención Primaria a la Especializada. Sociedad Española de Medicina de Familia (semFYC) y Sociedad Española de Neumología y Cirugía Torácica (SEPAR); 2010. http://​www.​guiasalud.​es/​GPC/​GPC_​468_​EPOC_​AP_​AE.​pdf. Accessed 30 Aug 2016.
2.
go back to reference Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012;7:457–94.CrossRefPubMedPubMedCentral Rycroft CE, Heyes A, Lanza L, Becker K. Epidemiology of chronic obstructive pulmonary disease: a literature review. Int J Chron Obstruct Pulmon Dis. 2012;7:457–94.CrossRefPubMedPubMedCentral
3.
go back to reference Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64:863–8.CrossRefPubMed Miravitlles M, Soriano JB, García-Río F, et al. Prevalence of COPD in Spain: Impact of undiagnosed COPD on quality of life and daily life activities. Thorax. 2009;64:863–8.CrossRefPubMed
4.
go back to reference Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11(1):1.CrossRef Glaab T, Vogelmeier C, Buhl R. Outcome measures in chronic obstructive pulmonary disease (COPD): strengths and limitations. Respir Res. 2010;11(1):1.CrossRef
5.
go back to reference Almagro P, Martinez-Camblor P, Soriano JB, et al. Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. PLoS One. 2014;9(2):e89866.CrossRefPubMedPubMedCentral Almagro P, Martinez-Camblor P, Soriano JB, et al. Finding the best thresholds of FEV1 and dyspnea to predict 5-year survival in COPD patients: the COCOMICS study. PLoS One. 2014;9(2):e89866.CrossRefPubMedPubMedCentral
7.
go back to reference Casanova C, Marin JM, Martinez-Gonzalez C, et al. New GOLD classification: longitudinal data on group assignment. Respir Res. 2014;15(1):1.CrossRef Casanova C, Marin JM, Martinez-Gonzalez C, et al. New GOLD classification: longitudinal data on group assignment. Respir Res. 2014;15(1):1.CrossRef
8.
go back to reference Lange P, Marott JL, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–81.CrossRefPubMed Lange P, Marott JL, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the new GOLD classification: a study of the general population. Am J Respir Crit Care Med. 2012;186(10):975–81.CrossRefPubMed
9.
go back to reference Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med. 2013;1(1):43–50.CrossRefPubMed Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective cohort study. Lancet Respir Med. 2013;1(1):43–50.CrossRefPubMed
10.
go back to reference Grupo de Trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC). Arch Bronconeumol. 2012;48:2–58. Grupo de Trabajo de GesEPOC. Guía de Práctica Clínica para el Diagnóstico y Tratamiento de Pacientes con Enfermedad Pulmonar Obstructiva Crónica (EPOC) - Guía Española de la EPOC (GesEPOC). Arch Bronconeumol. 2012;48:2–58.
11.
go back to reference van Dijk WD, van den Bemt L, van den Haak-Rongen S, et al. Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res. 2011;12:151–62.CrossRefPubMedPubMedCentral van Dijk WD, van den Bemt L, van den Haak-Rongen S, et al. Multidimensional prognostic indices for use in COPD patient care. A systematic review. Respir Res. 2011;12:151–62.CrossRefPubMedPubMedCentral
12.
go back to reference Celli BR, Cote CG, Marín JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.CrossRefPubMed Celli BR, Cote CG, Marín JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med. 2004;350:1005–12.CrossRefPubMed
13.
go back to reference Chavannes NH, Jones RCM, Postma DS, Rennard S. Using COPD multidimensional indices in routine clinical practice: DOSE meets all criteria. Prim Care Respir J. 2012;21(3):245–6.CrossRefPubMed Chavannes NH, Jones RCM, Postma DS, Rennard S. Using COPD multidimensional indices in routine clinical practice: DOSE meets all criteria. Prim Care Respir J. 2012;21(3):245–6.CrossRefPubMed
14.
go back to reference Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374(9691):704–11.CrossRefPubMed Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet. 2009;374(9691):704–11.CrossRefPubMed
15.
go back to reference Puhan MA, Hansel NN, Sobradillo P, et al. Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts. BMJ Open. 2012;2(6):e002152.CrossRefPubMedPubMedCentral Puhan MA, Hansel NN, Sobradillo P, et al. Large-scale international validation of the ADO index in subjects with COPD: an individual subject data analysis of 10 cohorts. BMJ Open. 2012;2(6):e002152.CrossRefPubMedPubMedCentral
16.
go back to reference Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103(5):692–9.CrossRefPubMed Soler-Cataluña JJ, Martínez-García MA, Sánchez LS, Tordera MP, Sánchez PR. Severe exacerbations and BODE index: two independent risk factors for death in male COPD patients. Respir Med. 2009;103(5):692–9.CrossRefPubMed
17.
go back to reference Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014;50:1–16.PubMed Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Spanish guideline for COPD (GesEPOC). Update 2014. Arch Bronconeumol. 2014;50:1–16.PubMed
18.
go back to reference Jones R, Donaldson G, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009;180(12):1189–95.CrossRefPubMed Jones R, Donaldson G, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med. 2009;180(12):1189–95.CrossRefPubMed
19.
go back to reference Sundh J, Janson C, Lisspers K, et al. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE ) index is predictive of mortality in COPD. Prim Care Resp J. 2012;21(3):295–301. Sundh J, Janson C, Lisspers K, et al. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE ) index is predictive of mortality in COPD. Prim Care Resp J. 2012;21(3):295–301.
20.
go back to reference Miravitlles M, Llor C, de Castellar R, et al. Validation of the COPD severity score for use in primary care: the NEREA study. Eur Respir J. 2009;33(3):519–27.CrossRefPubMed Miravitlles M, Llor C, de Castellar R, et al. Validation of the COPD severity score for use in primary care: the NEREA study. Eur Respir J. 2009;33(3):519–27.CrossRefPubMed
21.
go back to reference Rolink M, van Dijk W, van den Haak-Rongen S, et al. Using the DOSE index to predict changes in health status of patients with COPD: a prospective cohort study. Prim Care Respir J. 2013;22:169–74.CrossRefPubMed Rolink M, van Dijk W, van den Haak-Rongen S, et al. Using the DOSE index to predict changes in health status of patients with COPD: a prospective cohort study. Prim Care Respir J. 2013;22:169–74.CrossRefPubMed
22.
go back to reference Almagro P, Castro A. Helping COPD patients change health behavior in order to improve their quality of life. Int J Chron Obstruct Pulmon Dis. 2013;8:335–45.CrossRefPubMedPubMedCentral Almagro P, Castro A. Helping COPD patients change health behavior in order to improve their quality of life. Int J Chron Obstruct Pulmon Dis. 2013;8:335–45.CrossRefPubMedPubMedCentral
24.
go back to reference von Leupoldt A, Fritzsche A, Trueba AF, Meuret AE, Ritz T. Behavioral medicine approaches to chronic obstructive pulmonary disease. Ann Behav Med. 2012;44(1):52–65.CrossRef von Leupoldt A, Fritzsche A, Trueba AF, Meuret AE, Ritz T. Behavioral medicine approaches to chronic obstructive pulmonary disease. Ann Behav Med. 2012;44(1):52–65.CrossRef
26.
go back to reference Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40:373–83.CrossRefPubMed
27.
go back to reference Frei A, Muggensturm P, Putcha N, et al. Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index. J Clin Epidemiol. 2014;67(8):904–11.CrossRefPubMed Frei A, Muggensturm P, Putcha N, et al. Five comorbidities reflected the health status in patients with chronic obstructive pulmonary disease: the newly developed COMCOLD index. J Clin Epidemiol. 2014;67(8):904–11.CrossRefPubMed
28.
go back to reference Harrell F. Regression modelling strategies: with applications to linear models, logistic regression, and survival analysis. 2nd ed. New York: Springer; 2015.CrossRef Harrell F. Regression modelling strategies: with applications to linear models, logistic regression, and survival analysis. 2nd ed. New York: Springer; 2015.CrossRef
29.
31.
go back to reference Chavannes N, Ställberg B, Lisspers K, et al. UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance knowledge. Prim Care Respir J. 2010;19(4):408.CrossRefPubMed Chavannes N, Ställberg B, Lisspers K, et al. UNLOCK: Uncovering and Noting Long-term Outcomes in COPD to enhance knowledge. Prim Care Respir J. 2010;19(4):408.CrossRefPubMed
32.
go back to reference Kruis AL, Ställberg B, Jones RCM, et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS ONE. 2014;9(3):e90145.CrossRefPubMedPubMedCentral Kruis AL, Ställberg B, Jones RCM, et al. Primary care COPD patients compared with large pharmaceutically-sponsored COPD studies: an UNLOCK validation study. PLoS ONE. 2014;9(3):e90145.CrossRefPubMedPubMedCentral
33.
go back to reference Moons KGM, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73.CrossRefPubMed Moons KGM, Altman DG, Reitsma JB, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): explanation and elaboration. Ann Intern Med. 2015;162(1):W1–73.CrossRefPubMed
34.
go back to reference Soriano JB, Alfageme I, Almagro P, et al. Distribution and prognostic validity of the new GOLD grading classification. Chest. 2013;143(3):694–702.CrossRefPubMed Soriano JB, Alfageme I, Almagro P, et al. Distribution and prognostic validity of the new GOLD grading classification. Chest. 2013;143(3):694–702.CrossRefPubMed
35.
go back to reference Jones R, Price D, Chavannes N, et al. GOLD COPD categories are not fit for purpose in primary care. Lancet Respir Med. 2013;1(1):e17.CrossRef Jones R, Price D, Chavannes N, et al. GOLD COPD categories are not fit for purpose in primary care. Lancet Respir Med. 2013;1(1):e17.CrossRef
36.
go back to reference Oga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K. Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:521–6.CrossRefPubMedPubMedCentral Oga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K. Predictive properties of different multidimensional staging systems in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2011;6:521–6.CrossRefPubMedPubMedCentral
Metadata
Title
External validation of multidimensional prognostic indices (ADO, BODEx and DOSE) in a primary care international cohort (PROEPOC/COPD cohort)
Authors
Maite Espantoso-Romero
Miguel Román Rodríguez
Ana Duarte-Pérez
Jaime Gonzálvez-Rey
Pedro A. Callejas-Cabanillas
Durdica Kasuba Lazic
Berta Anta-Agudo
Pere Torán Monserrat
Rosa Magallon-Botaya
Biljana Gerasimovska Kitanovska
Heidrun Lingner
Radost S. Assenova
Claudia Iftode
Francisco Gude-Sampedro
Ana Clavería
On behalf of the PROEPOC/COPD study group
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Pulmonary Medicine / Issue 1/2016
Electronic ISSN: 1471-2466
DOI
https://doi.org/10.1186/s12890-016-0305-2

Other articles of this Issue 1/2016

BMC Pulmonary Medicine 1/2016 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.